vs
Amneal Pharmaceuticals, Inc.（AMRX）与利氏兄弟拍卖行（RBA）财务数据对比。点击上方公司名可切换其他公司
利氏兄弟拍卖行的季度营收约是Amneal Pharmaceuticals, Inc.的1.5倍（$1.2B vs $814.3M），利氏兄弟拍卖行净利率更高（9.1% vs 4.3%，领先4.8%），Amneal Pharmaceuticals, Inc.同比增速更快（11.5% vs 5.4%），利氏兄弟拍卖行自由现金流更多（$186.5M vs $108.5M），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（11.1% vs 6.3%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
利氏兄弟拍卖行（股票代码RBA）是全球知名的工业资产拍卖服务商，注册地位于加拿大，属公开上市企业，总部设在美国伊利诺伊州韦斯特切斯特，普通股同时在多伦多证券交易所与纽约证券交易所挂牌交易。
AMRX vs RBA — 直观对比
营收规模更大
RBA
是对方的1.5倍
$814.3M
营收增速更快
AMRX
高出6.1%
5.4%
净利率更高
RBA
高出4.8%
4.3%
自由现金流更多
RBA
多$78.0M
$108.5M
两年增速更快
AMRX
近两年复合增速
6.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $1.2B |
| 净利润 | $35.1M | $109.7M |
| 毛利率 | 36.5% | — |
| 营业利润率 | 13.8% | 14.7% |
| 净利率 | 4.3% | 9.1% |
| 营收同比 | 11.5% | 5.4% |
| 净利润同比 | 212.9% | -7.4% |
| 每股收益（稀释后） | $0.10 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXRBA
| Q4 25 | $814.3M | $1.2B | ||
| Q3 25 | $784.5M | $1.1B | ||
| Q2 25 | $724.5M | $1.2B | ||
| Q1 25 | $695.4M | $1.1B | ||
| Q4 24 | $730.5M | $1.1B | ||
| Q3 24 | $702.5M | $981.8M | ||
| Q2 24 | $701.8M | $1.1B | ||
| Q1 24 | $659.2M | $1.1B |
净利润AMRXRBA
| Q4 25 | $35.1M | $109.7M | ||
| Q3 25 | $2.4M | $95.5M | ||
| Q2 25 | $22.4M | $109.8M | ||
| Q1 25 | $12.2M | $113.4M | ||
| Q4 24 | $-31.1M | $118.5M | ||
| Q3 24 | $-156.0K | $76.1M | ||
| Q2 24 | $6.0M | $111.1M | ||
| Q1 24 | $-91.6M | $107.4M |
毛利率AMRXRBA
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 36.1% | — |
营业利润率AMRXRBA
| Q4 25 | 13.8% | 14.7% | ||
| Q3 25 | 9.0% | 14.5% | ||
| Q2 25 | 15.4% | 15.9% | ||
| Q1 25 | 14.4% | 17.1% | ||
| Q4 24 | 10.4% | 18.1% | ||
| Q3 24 | 12.6% | 15.6% | ||
| Q2 24 | 13.6% | 18.4% | ||
| Q1 24 | -1.6% | 18.7% |
净利率AMRXRBA
| Q4 25 | 4.3% | 9.1% | ||
| Q3 25 | 0.3% | 8.7% | ||
| Q2 25 | 3.1% | 9.3% | ||
| Q1 25 | 1.8% | 10.2% | ||
| Q4 24 | -4.3% | 10.4% | ||
| Q3 24 | -0.0% | 7.8% | ||
| Q2 24 | 0.9% | 10.1% | ||
| Q1 24 | -13.9% | 10.1% |
每股收益（稀释后）AMRXRBA
| Q4 25 | $0.10 | $0.53 | ||
| Q3 25 | $0.01 | $0.43 | ||
| Q2 25 | $0.07 | $0.53 | ||
| Q1 25 | $0.04 | $0.55 | ||
| Q4 24 | $-0.10 | $0.58 | ||
| Q3 24 | $0.00 | $0.36 | ||
| Q2 24 | $0.02 | $0.54 | ||
| Q1 24 | $-0.30 | $0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $531.5M |
| 总债务越低越好 | $2.6B | $2.3B |
| 股东权益账面价值 | $-70.8M | $5.6B |
| 总资产 | $3.7B | $12.1B |
| 负债/权益比越低杠杆越低 | — | 0.42× |
8季度趋势，按日历期对齐
现金及短期投资AMRXRBA
| Q4 25 | $282.0M | $531.5M | ||
| Q3 25 | $201.2M | $674.7M | ||
| Q2 25 | $71.5M | $710.2M | ||
| Q1 25 | $59.2M | $578.1M | ||
| Q4 24 | $110.6M | $533.9M | ||
| Q3 24 | $74.0M | $650.7M | ||
| Q2 24 | $43.8M | $599.5M | ||
| Q1 24 | $46.5M | $462.8M |
总债务AMRXRBA
| Q4 25 | $2.6B | $2.3B | ||
| Q3 25 | $2.6B | $2.6B | ||
| Q2 25 | $2.2B | $2.6B | ||
| Q1 25 | $2.2B | $2.6B | ||
| Q4 24 | $2.4B | $2.6B | ||
| Q3 24 | $2.4B | $2.7B | ||
| Q2 24 | $2.4B | $2.8B | ||
| Q1 24 | $2.4B | $2.9B |
股东权益AMRXRBA
| Q4 25 | $-70.8M | $5.6B | ||
| Q3 25 | $-109.5M | $5.5B | ||
| Q2 25 | $-112.1M | $5.5B | ||
| Q1 25 | $-131.7M | $5.3B | ||
| Q4 24 | $-109.3M | $5.2B | ||
| Q3 24 | $-93.4M | $5.2B | ||
| Q2 24 | $-57.5M | $5.2B | ||
| Q1 24 | $-63.7M | $5.1B |
总资产AMRXRBA
| Q4 25 | $3.7B | $12.1B | ||
| Q3 25 | $3.6B | $12.2B | ||
| Q2 25 | $3.4B | $12.2B | ||
| Q1 25 | $3.4B | $11.9B | ||
| Q4 24 | $3.5B | $11.8B | ||
| Q3 24 | $3.5B | $11.9B | ||
| Q2 24 | $3.5B | $12.1B | ||
| Q1 24 | $3.5B | $12.0B |
负债/权益比AMRXRBA
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | 0.47× | ||
| Q2 25 | — | 0.47× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | — | 0.50× | ||
| Q3 24 | — | 0.52× | ||
| Q2 24 | — | 0.55× | ||
| Q1 24 | — | 0.58× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $255.2M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $186.5M |
| 自由现金流率自由现金流/营收 | 13.3% | 15.5% |
| 资本支出强度资本支出/营收 | 2.7% | 5.7% |
| 现金转化率经营现金流/净利润 | 3.72× | 2.33× |
| 过去12个月自由现金流最近4个季度 | $269.9M | $719.2M |
8季度趋势，按日历期对齐
经营现金流AMRXRBA
| Q4 25 | $130.3M | $255.2M | ||
| Q3 25 | $118.5M | $239.7M | ||
| Q2 25 | $83.8M | $326.5M | ||
| Q1 25 | $7.4M | $156.8M | ||
| Q4 24 | $118.1M | $184.5M | ||
| Q3 24 | $141.8M | $285.4M | ||
| Q2 24 | $39.7M | $337.3M | ||
| Q1 24 | $-4.4M | $124.8M |
自由现金流AMRXRBA
| Q4 25 | $108.5M | $186.5M | ||
| Q3 25 | $106.2M | $188.5M | ||
| Q2 25 | $61.0M | $241.7M | ||
| Q1 25 | $-5.8M | $102.5M | ||
| Q4 24 | $102.9M | $127.9M | ||
| Q3 24 | $124.8M | $248.5M | ||
| Q2 24 | $29.0M | $308.6M | ||
| Q1 24 | $-13.6M | $79.6M |
自由现金流率AMRXRBA
| Q4 25 | 13.3% | 15.5% | ||
| Q3 25 | 13.5% | 17.3% | ||
| Q2 25 | 8.4% | 20.4% | ||
| Q1 25 | -0.8% | 9.2% | ||
| Q4 24 | 14.1% | 11.2% | ||
| Q3 24 | 17.8% | 25.3% | ||
| Q2 24 | 4.1% | 28.2% | ||
| Q1 24 | -2.1% | 7.5% |
资本支出强度AMRXRBA
| Q4 25 | 2.7% | 5.7% | ||
| Q3 25 | 1.6% | 4.7% | ||
| Q2 25 | 3.2% | 7.2% | ||
| Q1 25 | 1.9% | 4.9% | ||
| Q4 24 | 2.1% | 5.0% | ||
| Q3 24 | 2.4% | 3.8% | ||
| Q2 24 | 1.5% | 2.6% | ||
| Q1 24 | 1.4% | 4.2% |
现金转化率AMRXRBA
| Q4 25 | 3.72× | 2.33× | ||
| Q3 25 | 50.00× | 2.51× | ||
| Q2 25 | 3.74× | 2.97× | ||
| Q1 25 | 0.61× | 1.38× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 3.75× | ||
| Q2 24 | 6.62× | 3.04× | ||
| Q1 24 | — | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
RBA
| Buyer Revenue | $577.2M | 48% |
| Seller Revenue | $255.2M | 21% |
| CA | $199.0M | 17% |
| Other | $124.7M | 10% |
| AU | $47.3M | 4% |
